Based in Mainz (Germany), Ganymed is a Biopharma developing immunotherapies to tackle cancer, having joined forces with BioNTech (Germany’s larget private Biotech) 2 years ago to create one of the largest research centres in the country.
Ganymed is developing a new class of immunotherapies dubbed ideal monoclonal antibodies (IMABs). This technology aims to do something similar to Nanobiotix‘ localised radiotherapy – but instead to work for anticancer antibodies.
IMABs are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This tumor specificity means that anticancer potency can be increased, without a corresponding increase in toxicity.